← Back to Search

CAR T-cell Therapy

CART-PSMA-TGFβRDN for Prostate Cancer

Phase 1

Waitlist Available

Research Sponsored by Tceleron Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 15 years

Awards & highlights

Study Summary

This trial is testing a new cancer treatment that uses genetically modified T cells to attack prostate cancer cells. The goal is to see if the treatment is safe and works well against the cancer.

Eligible Conditions

Metastatic Castration Resistant Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cohort Expansion: Safety of CART-PSMA-TGFβRDN

Dose Escalation: Dose Identification of CART-PSMA-TGFβRDN

Secondary outcome measures

Feasibility of CART-PSMA-TGFβRDN

Peripheral expansion and persistence of CART-PSMA-TGFβRDN

Preliminary efficacy of CART-PSMA-TGFβRDN as assessed by biochemical Objective Response Rate (ORR)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dose EscalationExperimental Treatment4 Interventions

Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cyclophosphamide

1995

Completed Phase 3

~3770

Fludarabine

2012

Completed Phase 3

~1100

Anakinra

2016

Completed Phase 4

~2240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Tceleron Therapeutics, Inc.Lead Sponsor

2 Previous Clinical Trials

19 Total Patients Enrolled

Tmunity TherapeuticsLead Sponsor

6 Previous Clinical Trials

133 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent might CART-PSMA-TGFβRDN be hazardous to patients?

"Our team at Power have rated CART-PSMA-TGFβRDN a 1 on the safety scale due to only limited data being available regarding its efficacy and risk profile."

Answered by AI

Is there an ongoing recruitment process for participants of this experiment?

"This study is not taking on new participants at this moment. It was first published in November 2019 and last adjusted July of 2022. If you are interested, there are 1258 trials admitting patients with castration therapy and 919 clinical studies signing up candidates for CART-PSMA-TGFβRDN treatment."

Answered by AI

Are there various locations administering this clinical experiment in North America?

"This clinical trial is presently running at 9 sites, including those in Kansas City, Pittsburgh and Saint Louis. To reduce the burden of travel on any potential participant, it would be wise to select a site that is geographically closest."

Answered by AI

Have any other investigations looked into CART-PSMA-TGFβRDN?

"Initially investigated in 1997 by City of Hope Comprehensive Cancer Center, CART-PSMA-TGFβRDN has since seen 1343 experimental runs. Currently, there are 919 active trials primarily taking place in Kansas City, Kansas."

Answered by AI

What is the total number of participants enrolled in this clinical trial?

"This clinical trial is no longer enrolling participants, having been initially posted in November 2019 and most recently edited on July 20th 2022. Luckily there are 1258 trials searching for volunteers with castration issues and 919 studies actively recruiting patients for CART-PSMA-TGFβRDN treatment."

Answered by AI

To what medical conditions is the CART-PSMA-TGFβRDN therapeutic approach employed?

"The drug CART-PSMA-TGFβRDN is regularly utilized to treat malignancies of the lung, but can also be employed in managing systemic juvenile idiopathic arthritis (sjia), multiple sclerosis, leukemia and myelocytic acute."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

2019. "A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04227275.